REPRODUCTIVE STRESS; MEASUREMENT, MECHANISMS AND MANAGEMENT, CORPORATION

Biotech · Private

High-throughput screening (HTS) assays using human embryonic stem cells (hESCs) to test drug toxicity and developmental risks in first-trimester pregnancy

Grants
$450K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Embryonic stem cell high throughput screen accurately reports toxic stress$225,000
Federal grantDepartment of Health and Human Services · Phase I · Stress forces huESC differentiation; confirmation as an accurate DevTox HTS$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2111FRUGI BIOTECHNOLOGY INC.——
2112APC BIO INNOVATIONS INC——
2113ABILITY DYNAMICS, L.L.C.—$1.5M
2114REPRODUCTIVE STRESS; MEASUREMENT, MECHANISMS AND MANAGEMENT, CORPORATION——
2115BRIACELL THERAPEUTICS CORP—$34M
2116General Folders Inc.—$20K
2117Renasant Bio—$55M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.